ACIP recommends booster doses of MenB vaccines for people at increased risk of MenB disease. Booster doses should be administered to people in the following groups as long as increased risk remains:
- People with functional or anatomic asplenia, including sickle cell disease
- People with persistent complement component deficiency (an immune system disorder)
- People who take a complement inhibitor (eculizumab [Soliris] or ravulizumab [Ultomiris])
- Microbiologists who routinely work with meningococcal isolates
- Previously vaccinated people who are at risk during a meningococcal B disease outbreak
Because protective antibody levels produced by the primary series begin to wane within 1–2 years, the first booster dose is recommended one year after completion of the primary series, with subsequent booster doses every 2–3 years as long as increased risk remains. Previously vaccinated people identified by public health as being at risk during a meningococcal B outbreak should receive a booster dose if it has been at least one year since completion of their primary series, though depending upon the specific circumstances, public health may recommend a booster dose as little as 6 months after completion of the primary series.